Cdk4 Inhibitor III is a cell-permeable dioxobenzothiazole compound that acts a selective Cdk4 inhibitor (IC50 = 6.0 mM for Cdk4/D1 and > 200 mM for Cdk2/A). Cdk4 Inhibitor III exhibits better cytotoxic potential against cancer cells (IC50 = 0.61, 1.08, 0.30, and 1.21 mg/ml against A 549, Col 1, HepG2 tumor cells, respectively) than Cisplatin.
Ryu, C.K., et al. 2000. Bioorg. Med. Chem. Lett. 10, 461.